Diabetes
Conditions
Brief summary
This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).
Interventions
DRUGPlacebo, RVX000222
capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
DRUGRVX000222
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Sponsors
Baker Heart and Diabetes Institute
Nucleus Network Ltd
Resverlogix Corp
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Males aged 18-70 years, inclusive * Body mass index (BMI): 25-40 kg/m2 * HDL cholesterol plasma levels: ≤1.4 mmol/L * Pre-diabetes: Either impaired fasting glucose (IFG; 6.1-6.9mmol/L) or impaired glucose tolerance (IGT; 2 hour OGTT glucose 7.8-11.0mmol/L, WHO classification) as measured at Visit 1 * No current use or need for prescription or over-the-counter medication within four days of Visit 1 * Have given signed informed consent to participate in the study
Exclusion criteria
* Identification of any other medical condition requiring immediate therapeutic intervention * Has received any over-the-counter medication including vitamins, herbal, or dietary supplements within four days of Visit 1 unless prior approval from the Investigator * Tobacco use within six months of Visit 1 (including cigarettes, pipes, chewing tobacco) * Elective surgery requiring general anaesthesia during the course of the study * Clinically significant heart disease at Visit 1 * Clinically significant abnormal ECG at Visit 1 * Evidence of renal impairment defined as serum creatinine \>1.5 mg/dL (133 μmol/L) or creatinine clearance of \<60 mL/min * History of hypertension or supine SBP \>160mmHg or DBP \>95mmHg as measured at Visit 1 * Evidence of type 2 diabetes (fasting plasma glucose ≥7.0mmol/L; 2 hour OGTT glucose ≥11.1mmol/L) * Evidence of liver disease defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin \>1.5 x upper limit of normal (ULN) at Visit 1 * History of malignancy within past 5 years * History or evidence of drug or alcohol abuse within 12 months of Visit 1 * Use of other investigational drugs and/or devices at the time of enrolment, or within 30 days of Visit 1 * History of non-compliance to medical regimens or unwillingness to comply with the study protocol * Any condition that in the opinion of the Investigators would confound the evaluation and interpretation of the data * Persons directly involved in the execution of the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma glucose following treatment with RVX000222 compared to placebo | 29-33 days | The change in postprandial plasma glucose, defined as area under the glucose curve (AUGC) during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo | 29-33 days | The change in indices of insulin secretion (β-cell function) and insulin sensitivity during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo. |
Countries
Australia
Outcome results
None listed